A pMHC-specific CD8+ T cell approach has the most clinically-proven benefit in AML of delivering a cell product that can persist in circulation while also maintaining a central memory phenotype with inducible cytotoxicity [11, 12, 42]. This evidence concerns the gene CD8A and acute myeloid leukemia.